HOME >> BIOLOGY >> NEWS
Higher blood levels of sitosterol may be associated with increased risk for coronary events

ORLANDO, Fla., Nov. 10, 2003 Results from a nested, case-control study showed that patients with both high coronary risk and higher blood levels of sitosterol (1) (a plant sterol) were at an increased risk of a major coronary event compared to similar patients with lower blood levels of the plant sterol. These results were presented today at the 2003 American Heart Association's Scientific Sessions. Very high levels of plant sterols in the blood (levels ranging from 200 to 1570 mol/L [2,3]) have been previously confirmed as a risk factor for coronary heart disease.(4)

In this study, 177 cases (patients who suffered myocardial infarction [MI] or sudden coronary death within 10 years of follow-up) were selected from the PROCAM (Prospective Cardiovascular Muenster) study population. Each case was matched to two controls (n=354) from PROCAM based on age, gender, smoking status and date of investigation. Phytosterol concentrations, including sitosterol, were measured in samples collected at baseline in order to determine an association between phytosterol blood levels and increased risk for future coronary events.

Results from the study, which was funded in part by Merck/Schering-Plough

Pharmaceuticals, showed that levels of sitosterol were higher in patients who suffered coronary events compared to the matched controls (5.03 3.44 mol/L vs. 4.31 2.38 mol/L, p=0.003).

In addition, results from this preliminary study showed that study patients with modestly elevated (5) levels of sitosterol (>5.25mol/L) and high LDL cholesterol (LDL-C) (=4.14 mmol/L) were at nearly double the risk of a major coronary event compared to those with high LDL-C and sitosterol in the lower ranges (=5.25mol/L; p=0.025). Men considered at high risk for coronary events (>20 percent in 10 years as calculated using the PROCAM algorithm), who also had modestly elevated levels of sitosterol were at an estimated three-fold increased risk compared to those with
'"/>

Contact: Jutta Reising, University of Muenster
vdv119@uni-muenster.de
49-251-832-2115
Porter Novelli
10-Nov-2003


Page: 1 2

Related biology news :

1. Higher fibre intake linked to later periods, scientists say
2. Study: Higher energy intake, obesity affects all age groups, not just youths
3. Basic Research and Higher Education Program Conference breaks new ground
4. Higher fat diets show same positive effects on LDLs as low fat diet
5. Higher obesity rates prevail among Dutch women exposed to famine in utero
6. New Hampshire Study Shows Well Water Has Higher Arsenic Levels Than Municipal Water
7. Higher Levels Of Protein May Predict Heart Disease
8. Software Helps Decipher Genomes Of Higher Organisms
9. New Research: Children Inhale Higher Percentage Of Pollution
10. New Analytical Methods Indicate Higher Folic Acid Concentration In Beans And Peas
11. Eating Less Fat At One Meal May Lead To Higher Fat Intake Later

Post Your Comments:
(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: